Drug intelligence / Profile preview

VX-A906

Development stage: Preclinical
Lead developer: VERAXA Biotech

Overview

VX-A906 is a discovery-stage therapeutic candidate being developed by VERAXA Biotech for the treatment of lung cancer and breast cancer. As of early 2024, specific details regarding the drug's molecular target and modality remain undisclosed. The program is part of VERAXA's pipeline of antibody-based therapies, which leverages proprietary microfluidic screening and site-specific protein modification technologies to develop candidates such as monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific T-cell engagers.

Beyond the preview

Go deeper on VX-A906.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX-A906.

Explore the full profile